B Vitamins

The eight B vitamins are coenzymes: small molecules that enzymes need in order to run the reactions of energy metabolism, DNA synthesis, and the clearing of a toxic amino acid called homocysteine. Classic deficiency — pellagra, beriberi, the anemia of B12 depletion — is rare in well-fed populations, so the modern question is not "am I deficient?" but "do I belong to a group whose intake or absorption is quietly compromised, and if so, what should I actually take?" The honest answer is that a generalised "B-complex for longevity" is mostly wasted money, while a few targeted uses are genuinely worth the trouble.

Who actually needs them

Strong for the four at-risk groups below; for everyone else, supplementing delivers no measurable benefit.

For a healthy adult eating animal products and a reasonable variety of plants, the B vitamins are abundant and the body recycles them efficiently. Four situations change that:

1. Vegetarians and especially vegans. Plant foods contain essentially no vitamin B12 — it is made by bacteria and reaches us through animal products. This group should supplement B12 without waiting for a test.
2. Long-term metformin users. Metformin interferes with the calcium-dependent step that lets the gut absorb the B12–intrinsic-factor complex, and a 16-year follow-up of the large US diabetes-prevention cohort confirmed a real, dose- and duration-dependent fall in B12 over years of use.^[1]
3. People on chronic acid suppression. Proton-pump inhibitors and H2-blockers cut the stomach acid needed to free B12 from food protein. Pharmacovigilance analysis finds the metformin-plus-acid-suppressant combination carries a compounded B12-deficiency risk beyond either drug alone.^[2]
4. Adults past about 60. Age-related atrophic gastritis becomes common, impairing the acid and intrinsic factor that dietary B12 needs; 10–30% of older adults absorb it poorly.

Outside these groups, mega-dosing a B-complex does not measurably improve energy, mood, or cognition in people who aren't deficient — a point worth holding onto, because the category is marketed almost entirely on the opposite promise.

The one cognitive result that holds up — and its catch

Moderate at best, and confined to a narrow subgroup — older adults with mild cognitive impairment and elevated homocysteine.

The headline reason people take B vitamins for the aging brain is homocysteine. This amino acid, a by-product of methionine metabolism, is toxic to neurons and blood vessels at elevated levels and is an independent risk factor for brain shrinkage and cognitive decline. Vitamins B6, B9 (folate), and B12 are the obligatory cofactors that clear it from the blood, so lowering homocysteine with B vitamins is biologically plausible.

The evidence is more conditional than the marketing. Pooled analyses are clear that in cognitively healthy adults with normal homocysteine, B-vitamin supplements do not improve memory or global cognition.^[3] The benefit, where it exists, is concentrated in older adults who already have mild cognitive impairment and elevated homocysteine — and even there it has been inconsistent across trials.^[4] The honest synthesis from broadly null pooled data is that the effect, if any, is small and confined to deficient or high-homocysteine subgroups.

The single trial that anchors the optimistic case is VITACOG, a British study in adults with mild cognitive impairment in which high-dose B6/B9/B12 slowed the whole-brain atrophy rate by 29.6% (0.76%/yr active vs 1.08%/yr placebo, P=0.001), rising to a 53.3% reduction in those in the top homocysteine quartile (>13 µmol/L).^[5] A later re-analysis sharpened the catch: the atrophy benefit appeared only in participants who already had high blood levels of omega-3. In those with good omega-3 status, B vitamins slowed brain shrinkage by about 40% (and up to ~46% in the subgroup with the most EPA, eicosapentaenoic acid, in their blood); in those with low omega-3 it did essentially nothing.^[6] The companion analysis found the same omega-3 dependence for cognitive decline.^[7] These figures come from a trial powered for atrophy rather than cognition, with unadjusted subgroup p-values, so the precise magnitudes are fragile even though the direction is real. Later metabolomic work on the same trial showed the B vitamins were reshaping homocysteine and neurotransmitter-related pathways, not acting through a single mechanism.^[8]

The practical message is a two-part one: the B-vitamin cognitive intervention is worth considering only in older adults with documented high homocysteine, and it is probably pointless without adequate omega-3 alongside it. See Omega-3 and Dementia prevention.

Vitamin B12: testing and form

Strong for repletion in the at-risk groups; the case for premium forms is Weak.

Deficiency is common enough to take seriously with age: roughly 6% of adults under 60 but around 20% of those over 60 are deficient or marginally depleted, which is the concrete basis for the over-60 recommendation above. One under-appreciated interaction sharpens the masking concern: when B12 status is low, a high serum folate has been associated with worse cognition and higher homocysteine and methylmalonic acid — a reason the fortification era makes adequate B12 matter more, not less.^[9]

Serum B12 is an insensitive test. The body defends blood levels at the expense of tissue stores, so a "normal" serum B12 can sit on top of genuine intracellular depletion. The functional markers — methylmalonic acid (MMA) and homocysteine — rise before serum B12 falls, which is why ambiguous cases should be confirmed with MMA or holotranscobalamin rather than serum B12 alone. Elevated MMA is itself associated with higher all-cause mortality in older and cardiorenal populations, making it a useful early-warning marker rather than just a deficiency test.^[10] The testing cadence for at-risk groups lives in Midlife labs.

On the form, the marketing runs ahead of the evidence. B12 is sold cheaply as cyanocobalamin and at a premium as methylcobalamin (the active coenzyme form). For correcting deficiency and raising blood B12, systematic reviews find the two essentially equivalent — high-dose oral or sublingual cyanocobalamin works fine for most people.^[11] Methylcobalamin's theoretical advantage (it skips a conversion step and acts as a direct methyl donor) is real biochemistry but has not translated into a meaningful clinical edge for routine repletion. If you want it, the cost is modest; just don't expect the form alone to do anything dramatic.

Dose: 25–250 µg/day for prevention in an at-risk group; 1000 µg/day for documented deficiency. High oral doses work even when absorption is impaired by drugs or atrophic gastritis, because 1–2% crosses the gut by passive diffusion independent of intrinsic factor. B12 is water-soluble with no established upper limit — oversupplementation is not a meaningful toxicity concern.

Folate: methylfolate versus folic acid

Moderate for the 5-MTHF-over-folic-acid case in adults; Strong for folic acid in neural-tube-defect prevention.

This is the form debate that actually matters. Natural food folate, the synthetic folic acid in fortified foods and cheap supplements, and 5-methyltetrahydrofolate (5-MTHF, the active circulating form) are not interchangeable.

Folic acid is biologically inert until the body reduces it, a multi-step conversion whose first enzyme (dihydrofolate reductase) has low and variable capacity in humans. High intakes can outrun it, leaving unmetabolised folic acid circulating in the blood — a state of uncertain long-term significance that can also mask the anemia which normally signals a hidden B12 deficiency, delaying its diagnosis. A large share of people also carry common variants in the MTHFR gene that impair the conversion of folate to its active form. Direct supplementation with 5-MTHF sidesteps the MTHFR bottleneck, produces a more durable drop in homocysteine, and avoids unmetabolised folic acid altogether.^[12] For these reasons 5-MTHF is the better default when folate supplementation is actually indicated.^[13]

One firm exception holds in the other direction: women who could become pregnant should ensure adequate folate for neural-tube-defect prevention, and folic acid is the form with the deepest evidence base in that specific context. The case for it is overwhelming at the population scale — mandatory folic-acid fortification cut neural-tube defects by 46% in Canada (1.58 to 0.86 per 1,000 births) and by roughly a quarter to a half across other fortifying countries.^[14] The 5-MTHF case is about optimisation in adults, not about overturning prenatal folic-acid guidance.

On the cancer question that the folic-acid debate inevitably raises: a randomised polyp-prevention trial (n=1,021) found that 1 mg/day folic acid did not prevent colorectal adenomas and was associated with more advanced and multiple lesions.^[15] That signal has not been confirmed in long-term follow-up or in meta-analyses of randomised trials (~50,000 participants) at fortification/supplement doses. The defensible reading is that timing and dose matter and supraphysiologic intakes warrant caution, but no large colorectal-cancer effect is established at fortification doses.

Vitamin B6: the one with a real toxicity ceiling

Caution — documented harm (peripheral neuropathy) above the intake limit; the cancer and fracture signals are Weak/observational.

B6 is the B vitamin most worth being careful with, because more is not safer. Chronically exceeding the intake limit over months to years can cause a reversible sensory peripheral neuropathy — tingling and numbness in the hands and feet. The European Food Safety Authority sets the tolerable upper limit for adults at 12 mg/day, far below the doses packed into many "energy" and "stress" B-complex formulas.^[16] Australia's regulator lowered its neuropathy-warning threshold to >10 mg/day in 2022, real-world corroboration of the risk. If you take a B-complex, check the B6 content against that ceiling. The active form, pyridoxal-5-phosphate (P5P), is sometimes preferred but does not exempt you from the dose caution.

Two observational signals reinforce why stand-alone high-dose B6/B12 products deserve particular suspicion — both are association data, vulnerable to confounding, not proof of harm. In the VITAL cohort (n=77,118), long-term individual-supplement use among men was tied to roughly doubled lung-cancer risk (B6 >20 mg/day HR 1.82, 95% CI 1.25–2.65; B12 >55 µg/day HR 1.98, 95% CI 1.32–2.97) — the 95% confidence interval is the range where the true effect most plausibly lies, and because both intervals sit entirely above 1.0, chance is an unlikely explanation — highest in current smokers, with no association in women and none from multivitamins.^[17] And in the Nurses' Health Study (n=75,864), combined high intake of B6 and B12 was associated with increased hip-fracture risk — though B12 alone carried no such signal, so older adults who genuinely need B12 should not be deterred.^[18] The recurring theme: caution is warranted when supplementing without a documented deficiency.

Niacin, NAD+, and the longevity-molecule question

Weak for the NAD+-booster longevity claims; a Caution signal now attaches to niacin/NAD+ metabolites.

Vitamin B3 is the precursor for NAD+ (nicotinamide adenine dinucleotide), the coenzyme central to energy metabolism, DNA repair, and the sirtuin enzymes that feature heavily in aging research. This is the biochemistry behind the NMN (nicotinamide mononucleotide) and nicotinamide riboside (NR) supplements sold as anti-aging compounds — and it is where the gap between mechanism and proven human benefit is widest. These precursors reliably raise blood NAD+, but the functional results in people have been small and inconsistent, and the longevity claims rest on animal data and surrogate markers rather than hard outcomes. The full, skeptical treatment of NMN and NR is in Geroprotectors; the short version is that the hype substantially outruns the evidence.

The older, cheaper end of B3 has a longer track record — and it has not aged well. Plain niacin (nicotinic acid) raises NAD+ severalfold and once anchored lipid therapy, but the two large modern trials retired it: AIM-HIGH was halted early for futility in 2011, and HPS2-THRIVE (n=25,673) found niacin added no cardiovascular benefit on top of statins while raising new-onset diabetes, infection, and bleeding.^[19] Its use is also limited by an uncomfortable prostaglandin-mediated flush, and its EFSA upper limit is correspondingly low at 10 mg/day for supplemental nicotinic acid. The other B3 form, nicotinamide, carries a much higher limit (900 mg/day). Neither is a longevity intervention for a healthy adult on current evidence.

A 2024 finding complicates the whole NAD+-booster story. The terminal niacin/NAD+ catabolites 2PY and 4PY were associated with elevated three-year major-adverse-cardiovascular-event risk across a discovery and two validation cohorts, and 4PY drove vascular inflammation in mice through an endothelial adhesion molecule (VCAM-1) that recruits inflammatory cells to the artery wall — a mechanistic plus associational signal, not yet interventional evidence.^[20] Because NR and NMN also raise these metabolites, this directly undercuts the rationale for the NAD+ boosters already treated skeptically above.

A further note: the long-held belief that NAD+ inevitably falls with age has been complicated by recent work showing blood NAD+ does not universally decline in healthy people, and that the depletion is tissue- and disease-specific — concentrated in conditions like neurodegeneration and certain cancers rather than tracking chronological age. That undercuts the simple "top up a universal deficit" rationale for NAD+ boosters in the well.

The rest of the complex

Weak as a longevity case, with two well-evidenced niche uses: riboflavin for migraine prophylaxis (Moderate) and thiamine repletion in defined at-risk groups (Strong).

The remaining B vitamins are essential coenzymes but rarely the limiting factor in a mixed diet, and none has earned a stand-alone longevity case:

• B1 (thiamine) feeds carbon into the energy-producing TCA (tricarboxylic acid) cycle and is critical for nerve function; deficiency is reversible and frequently missed. The at-risk set is broader than alcohol alone: chronic alcohol use disorder (the classic cause of Wernicke encephalopathy), pre- and post-bariatric surgery, refeeding syndrome, and heart failure on chronic loop diuretics — though the prevalence in stable outpatient heart failure is genuinely uncertain, with modern estimates well below the high figures from older literature.
• B2 (riboflavin) is a core electron carrier in the mitochondrial respiratory chain. Cell work suggests it can suppress senescent-cell accumulation under stress.^[21] It also uniquely lowers blood pressure — by roughly 6–13 mmHg systolic — specifically in people homozygous for the MTHFR 677TT variant (about 10% of the population), an early example of nutrition targeted to genotype rather than a general recommendation, though the riboflavin–blood-pressure trials were industry-funded (DSM).^[22] Separately, riboflavin has a well-established and cheap use it is rarely credited for: at 400 mg/day it roughly quadrupled migraine responders versus placebo (59% vs 15%, number-needed-to-treat 2.3).^[23]
• B5 (pantothenic acid) is the backbone of coenzyme A, needed for fat metabolism; dietary deficiency is almost unheard of.
• B7 (biotin) supports gluconeogenesis and participates in DNA-repair-related histone modification. Supplemental megadoses, common in hair-and-nail products, are mostly harmless but interfere with many laboratory immunoassays — including thyroid and troponin tests — and should be stopped before bloodwork.

EFSA has set no upper limit for B1, B2, B5, or B7 owing to the absence of toxicity even at high intakes.

Cardiovascular: prevention, not reversal

Strong — the randomized trials are clear that homocysteine-lowering with B vitamins does not prevent cardiovascular events.

Higher dietary intake and blood levels of several B vitamins (B1, B2, B3, B6, B9) correlate with a 10–20% lower stroke risk across two large US cohorts — but this is an observational dietary association, not evidence that taking the pills lowers risk.^[24] The randomised evidence is the more important and more sobering fact: the large trials that successfully lowered homocysteine with B vitamins did not reduce heart attacks, strokes, or cardiovascular death. HOPE-2 (n=5,522) cut homocysteine but left the primary cardiovascular composite unchanged;^[25] NORVIT and SEARCH in post-MI patients and VITATOPS in prior-stroke patients were likewise null. The 2017 Cochrane review — 15 RCTs, 71,422 participants — concluded that homocysteine-lowering with B vitamins does not prevent myocardial infarction, stroke, or death.^[26] Homocysteine looks more like a marker of vascular risk than a lever you can pull to change outcomes, and trials aimed at acutely reversing established arterial stiffness have been mixed at best.^[27]

The one apparent exception sharpens the rule. CSPPT randomised 20,702 Chinese hypertensive adults — a population with low baseline folate and no food fortification — to enalapril with or without folic acid, and the folic-acid arm cut first stroke by 21% (HR 0.79; 2.7% vs 3.4%) over 4.5 years, concentrated in those with the lowest folate.^[28] That is a deficiency-correction effect in an unfortified population, not a generalisable benefit for already-replete Western adults — which is exactly why the null Western trials and this positive one are consistent. B vitamins belong in the prevention-of-deficiency column, not the cardiovascular-drug column.

Practical summary

• Don't take a generic high-dose B-complex for longevity. In a non-deficient adult it does nothing measurable, and the B6 load in many formulas is a genuine downside.
• Supplement B12 if you are vegan/vegetarian, on long-term metformin or acid-suppressants, or over ~60. 25–250 µg/day for prevention, 1000 µg/day for documented deficiency.
• Confirm B12 status with MMA or holotranscobalamin, not serum B12 alone, and check homocysteine as a downstream readout of B6/B9/B12 status. Target homocysteine in the single digits (roughly below 10 µmol/L) rather than merely "in range." See Midlife labs.
• If you supplement folate, prefer 5-MTHF over folic acid — except for prenatal folic-acid guidance, which stands.
• The B-vitamin cognitive intervention (B6/B9/B12 in older adults with high homocysteine) is only worth trying alongside adequate omega-3.
• Take B vitamins in the morning with food. They are water-soluble and tied to daytime energy metabolism; evening high doses can disturb sleep in some people, and consistency matters more than timing.
• Skip the NAD+ boosters (NMN, NR) for now — see Geroprotectors.

Further reading

• Smith AD et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment (VITACOG). PLoS ONE 2010.^[29]
• Jernerén F et al. Brain atrophy in cognitively impaired elderly: the importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial. Am J Clin Nutr 2015.^[30]
• Martí-Carvajal AJ et al. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2017 (15 RCTs, 71,422 participants).^[31]
• Ferrell M, Hazen SL et al. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nat Med 2024.^[32]
• Brasky TM, White E, Chen CL. Long-term, supplemental, one-carbon-metabolism-related vitamin B use and lung cancer risk (VITAL). J Clin Oncol 2017.^[33]
• Aroda VR et al. Long-term Metformin Use and Vitamin B12 Deficiency in the DPP/DPPOS. J Clin Endocrinol Metab 2016.^[34]
• Ferreira Gonçalves A et al. Active folate versus folic acid: the role of 5-MTHF in human health. PMC 2022.^[35]
• Comparative review. Vitamin B12: natural versus synthetic forms of supplementation. PMC 2025.^[36]
• EFSA. Overview of tolerable upper intake levels. EFSA 2024.^[37]
• Methylmalonic acid and all-cause mortality. Front Nutr 2025.^[38]
• Zhang X et al. Intake of B vitamins and their circulating levels in relation to incident stroke in women and men: findings from two national prospective cohorts. Am J Prev Cardiol 2026.^[39]

---